Can Valeant keep its debt-fueled M&A binge going strong enough? That's the question

Serial dealmaker Valeant ($VRX) seems to have bounced back since its failed bid for Allergan ($AGN) in November. The Canadian pharma has since inked two deals and is rumored to have another one in the works. But its heavy debt load has some questioning whether it can deliver on its goal of becoming one of the world's top 5 drugmakers by 2016. More from FiercePharma

Suggested Articles

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.

The FDA approved GlaxoSmithKline's Nucala to treat hypereosinophilic syndrome, making it the first biologic approved for that disease.